Literature DB >> 1559298

Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function tests.

J Webster1, M D Page, J S Bevan, S H Richards, A G Douglas-Jones, M F Scanlon.   

Abstract

OBJECTIVE: To determine the factors influencing the outcome of transethmoidal partial hypophysectomy for suspected prolactinoma and the predictive value of pre and post-operative dynamic PRL function tests.
DESIGN: A retrospective study of patients undergoing surgery for a suspected prolactinoma in Cardiff between 1979 and 1989. PATIENTS: Eighty-two hyperprolactinaemic patients (75 women, seven men) diagnosed as having a prolactinoma on the basis of dynamic PRL function tests, radiological investigation and exclusion of other causes. MEASUREMENTS: TSH and PRL responses to domperidone (10 mg i.v.) and TRH (200 micrograms i.v.) measured preoperatively, 2 months post-operatively, and annually thereafter. CT scan performed preoperatively in 58 patients. Operative findings, including adenoma size, documented in each case.
RESULTS: Forty-two patients (51%) had microadenomas (less than 10 mm), 37 (46%) had macroadenomas and in three no tumour was found at operation. Preoperatively, normal responses of both TSH (incremental rise less than 2.0 mU/l) and PRL (greater than 100% rise) to domperidone were observed in two patients only: both had an abnormal vascular supply to the pituitary rather than an adenoma. Serum PRL was normalized in the early post-operative period (less than 72 h; 'early cure') in 65 patients (79%). The highest early cure rate (96%, n = 26) was in patients with adenomas of 5-9 mm, lower rates being achieved for lesions of 10-19 mm (80%, n = 30), less than 5 mm (63%, n = 19) or greater than or equal to 20 mm (57%, n = 7). The early cure rate was strongly correlated with preoperative PRL, ranging from 100% in patients with PRL less than 1000 mU/l (n = 13) to zero in those with PRL greater than 10,000 mU/l. Dopamine agonist therapy of between 5 weeks and 4 years duration prior to surgery was associated with a significantly reduced early cure rate (60 vs 94%, P less than 0.02) in macroadenoma but not microadenoma patients. Recurrent hyperprolactinaemia during mean follow-up of 51.7 months occurred in eight patients (12%), in five cases within 2 months of surgery and in the others at 26, 48 and 50 months. Recurrence could not be predicted from any preoperative parameter, but a serum PRL greater than 150 mU/l 1-3 days following microadenomectomy was associated with early recurrence and probably indicates failed surgery. An abnormal response of TSH to domperidone was documented 2 months post-operatively in 11/60 patients with normal basal PRL, and preceded all three late recurrences. Of four patients with abnormal responses of both PRL and TSH at this time, two have relapsed to date.
CONCLUSIONS: In carefully selected patients, partial hypophysectomy is an acceptable alternative to medical treatment for prolactinoma. Preoperatively, dynamic tests accurately identified those patients whose hyperprolactinaemia was non-adenomatous in origin and, post-operatively, identified a subgroup of patients at increased risk of late recurrence.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1559298     DOI: 10.1111/j.1365-2265.1992.tb02900.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  8 in total

1.  Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.

Authors:  D Kojo Hamilton; Mary Lee Vance; Paul T Boulos; Edward R Laws
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

2.  Microprolactinomas: why requiem for surgery?

Authors:  A Liuzzi; G Oppizzi
Journal:  J Endocrinol Invest       Date:  1996-03       Impact factor: 4.256

Review 3.  Classification and pathology of pituitary tumors.

Authors:  George Kontogeorgos
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

Review 4.  Pituitary tumors. Current concepts in diagnosis and management.

Authors:  D C Aron; J B Tyrrell; C B Wilson
Journal:  West J Med       Date:  1995-04

Review 5.  Treatment of hyperprolactinemia: a systematic review and meta-analysis.

Authors:  Amy T Wang; Rebecca J Mullan; Melanie A Lane; Ahmad Hazem; Chaithra Prasad; Nicola W Gathaiya; M Mercè Fernández-Balsells; Amy Bagatto; Fernando Coto-Yglesias; Jantey Carey; Tarig A Elraiyah; Patricia J Erwin; Gunjan Y Gandhi; Victor M Montori; Mohammad Hassan Murad
Journal:  Syst Rev       Date:  2012-07-24

6.  Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists.

Authors:  Muriel Babey; Rahel Sahli; Istvan Vajtai; Robert H Andres; Rolf W Seiler
Journal:  Pituitary       Date:  2011-09       Impact factor: 4.107

Review 7.  Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

8.  Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis.

Authors:  Xiangming Cai; Junhao Zhu; Jin Yang; Chao Tang; Zixiang Cong; Chiyuan Ma
Journal:  Chin Neurosurg J       Date:  2022-04-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.